Sign In
1 Apr 2019 07:00
PRESS RELEASE
Total Voting Rights
Guildford, UK - 1 April 2019: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.
The Company's issued share capital as at 31 March 2019 consisted of 46,161,438 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.
- Ends -
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) | |
Stuart Jackson (Chief Financial Officer) | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield (Nominated Adviser) | |
James Black (Broker) | |
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Mary-Jane Elliott | ergomed@consilium-comms.com |
Matthew Neal / Olivia Manser | |
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 |
Anne Hennecke |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
Follow the stocks
